Literature DB >> 31286431

Nuclear medical imaging as part of dementia diagnostics in psychiatric day-care clinics and inpatient care settings.

Jonathan Vogelgsang1, Bernhard Kis2, Katrin Radenbach2, Claus Wolff-Menzler2, Kiriaki Mavridou2, Charles Timäus2, Stephan Gyßer3, Jens Wiltfang2,4,5, Philipp Hessmann2.   

Abstract

BACKGROUND: Current guidelines support the use of nuclear medical imaging (NMI) techniques for differential diagnostics of certain cases of dementia. AIMS: We aimed at studying the association between using NMI and the accuracy of dementia diagnoses. Additionally, we evaluated the effect of conducting NMI on the duration of hospital treatment.
METHODS: This study was based on data collected according to §21 of the German hospital remuneration law, including relevant diagnostic and procedural codes for NMI in dementia patients. In total, more than 7.2 million cases treated in German psychiatric and somatic hospitals between 2015 and 2017 were included. Associations between the frequency of NMI and the accuracy of dementia diagnoses in terms of specific vs. unspecific diagnostic codes were analyzed using Fischer's exact test.
RESULTS: In total, 351,106 cases with a dementia diagnosis were encoded during the study period. NMI was performed in 1.03% or 0.15% of all patients with dementia in psychiatric or somatic clinics, respectively. In psychiatric clinics, the proportion of unspecific dementia diagnoses decreased from 20.86% in 2015 to 17.73% in 2017. NMI was mainly performed within psychiatric day-care settings. Interestingly, patients receiving NMI stayed shorter within day-care settings (8.1 ± 16.0 days) compared to inpatient settings (38.3 ± 44.7 days).
CONCLUSIONS: Nuclear medical imaging is often performed in psychiatric day-care settings. Further studies are warranted to understand the predictive diagnostic value of NMI in dementia diagnosis compared with clinical, CSF and structural imaging in different healthcare settings.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid-PET; Dementia; Nuclear medical imaging; Patient care

Mesh:

Year:  2019        PMID: 31286431     DOI: 10.1007/s40520-019-01257-9

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   3.636


  20 in total

Review 1.  Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia.

Authors:  Marina Boccardi; Cristina Festari; Daniele Altomare; Federica Gandolfo; Stefania Orini; Flavio Nobili; Giovanni B Frisoni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-30       Impact factor: 9.236

2.  The role of biomarkers and imaging in the clinical diagnosis of dementia.

Authors:  Antony J Bayer
Journal:  Age Ageing       Date:  2018-09-01       Impact factor: 10.668

Review 3.  A Systematic Review and Meta-Analysis of the Effectiveness of Acetylcholinesterase Inhibitors and Memantine in Treating the Cognitive Symptoms of Dementia.

Authors:  Ruth Knight; Mizanur Khondoker; Nicholas Magill; Robert Stewart; Sabine Landau
Journal:  Dement Geriatr Cogn Disord       Date:  2018-05-07       Impact factor: 2.959

4.  [The importance of molecular imaging (PET) in the diagnostics of dementia].

Authors:  M Tscheuschler; M Gebest; F Jessen; A Drzezga
Journal:  Nervenarzt       Date:  2018-07       Impact factor: 1.214

5.  The decreasing prevalence of reversible dementias: an updated meta-analysis.

Authors:  A Mark Clarfield
Journal:  Arch Intern Med       Date:  2003-10-13

6.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

Authors:  Christopher M Clark; Michael J Pontecorvo; Thomas G Beach; Barry J Bedell; R Edward Coleman; P Murali Doraiswamy; Adam S Fleisher; Eric M Reiman; Marwan N Sabbagh; Carl H Sadowsky; Julie A Schneider; Anupa Arora; Alan P Carpenter; Matthew L Flitter; Abhinay D Joshi; Michael J Krautkramer; Ming Lu; Mark A Mintun; Daniel M Skovronsky
Journal:  Lancet Neurol       Date:  2012-06-28       Impact factor: 44.182

7.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.

Authors:  Norman L Foster; Judith L Heidebrink; Christopher M Clark; William J Jagust; Steven E Arnold; Nancy R Barbas; Charles S DeCarli; R Scott Turner; Robert A Koeppe; Roger Higdon; Satoshi Minoshima
Journal:  Brain       Date:  2007-08-18       Impact factor: 13.501

Review 8.  Alzheimer disease: operating characteristics of PET--a meta-analysis.

Authors:  Meenal B Patwardhan; Douglas C McCrory; David B Matchar; Gregory P Samsa; Olivier T Rutschmann
Journal:  Radiology       Date:  2004-02-27       Impact factor: 11.105

9.  European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus.

Authors:  F Nobili; J Arbizu; F Bouwman; A Drzezga; F Agosta; P Nestor; Z Walker; M Boccardi
Journal:  Eur J Neurol       Date:  2018-07-20       Impact factor: 6.089

10.  Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.

Authors:  Ian McKeith; John O'Brien; Zuzana Walker; Klaus Tatsch; Jan Booij; Jacques Darcourt; Alessandro Padovani; Raffaele Giubbini; Ubaldo Bonuccelli; Duccio Volterrani; Clive Holmes; Paul Kemp; Naji Tabet; Ines Meyer; Cornelia Reininger
Journal:  Lancet Neurol       Date:  2007-04       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.